Zealand Pharma and Generate Biomedicines announced a collaboration to develop AI-designed multispecific protein treatments for obesity and other metabolic diseases.
The agreement initially covers two programs, with an option to add a third. Generate will lead research through candidate selection; Zealand will handle clinical development, regulatory submissions, and worldwide commercialization.
Generate will receive $30 million upfront and up to $35 million in early preclinical milestones. It may also earn nearly $1.2 billion in development, regulatory, and commercial milestones, plus tiered royalties on sales.
The deal broadens Zealand’s drug-development approach beyond its existing peptide and small-molecule work. The companies have not disclosed the specific biological targets.
Sources:
Zealand Pharma, Generate strike AI obesity drug deal ...
Generate Biomedicines and Zealand Pharma Enter
Zealand Pharma Makes Deal With Generate Worth Up to $1.2 Billion
Zealand Pharma and Generate Biomedicines Enter
Zealand inks $1.2B Generate pact to add multispecific ...
Zealand Pharma, Generate Biomedicines Partner To ...
Zealand Pharma and Generate Biomedicines strike AI drug deal By Investing.com
Zealand Pharma, Generate strike AI obesity drug deal ...
Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate
Gain a Regulatory Edge in Early-Phase Drug Development